LLY

994.01

-1.48%↓

JNJ

201.82

+0.01%↑

ABBV

224.15

-0.92%↓

UNH

324.14

-1.93%↓

AZN

90.51

+0.37%↑

LLY

994.01

-1.48%↓

JNJ

201.82

+0.01%↑

ABBV

224.15

-0.92%↓

UNH

324.14

-1.93%↓

AZN

90.51

+0.37%↑

LLY

994.01

-1.48%↓

JNJ

201.82

+0.01%↑

ABBV

224.15

-0.92%↓

UNH

324.14

-1.93%↓

AZN

90.51

+0.37%↑

LLY

994.01

-1.48%↓

JNJ

201.82

+0.01%↑

ABBV

224.15

-0.92%↓

UNH

324.14

-1.93%↓

AZN

90.51

+0.37%↑

LLY

994.01

-1.48%↓

JNJ

201.82

+0.01%↑

ABBV

224.15

-0.92%↓

UNH

324.14

-1.93%↓

AZN

90.51

+0.37%↑

Home・Elenco Azioni・Cassava Sciences Inc

Cassava Sciences Inc

Aperta

SettoreSettore sanitario

3.25 1.88

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

3.12

Massimo

3.25

Metriche Chiave
By Trading Economics
Entrata	33M -11M
Vendite	840K 840K
EPS	-0.22
Margine di Profitto	-1,286.548
Dipendenti	30
EBITDA	35M -11M

Raccomandazioni
By TipRanks
Raccomandazioni	Acquista
Previsioni per 12 mesi	+150.78% upside

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	-4.3M 142M
Apertura precedente	1.37
Chiusura precedente	3.25

Notizie sul Sentiment di mercato

By Acuity

34%

66%

105 / 374 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Weak Bearish Evidence

1.56 / 1.7 Supporto e resistenza

Cassava Sciences Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

7 dic 2025, 23:00 UTC

Acquisizioni, Fusioni, Takeovers

Brookfield, GIC Agree $4.5 Billion Deal for Australia's National Storage -- Update

5 dic 2025, 21:08 UTC

Acquisizioni, Fusioni, Takeovers

Meta Platforms Buys AI-Device Maker Limitless

5 dic 2025, 19:39 UTC

I principali Market Mover

Parsons' FAA Bid Loss Clouds Outlook After Rocky Year for Contractors

5 dic 2025, 19:17 UTC

Acquisizioni, Fusioni, Takeovers

Constellation Energy Agrees to Divest Assets to Finalize Calpine Deal

7 dic 2025, 23:42 UTC

Discorsi di Mercato

Nikkei May Rise on Weaker Yen -- Market Talk

7 dic 2025, 23:05 UTC

Discorsi di Mercato

RBA Set to Remain 'Emphatically' On Hold, Westpac Says -- Market Talk

7 dic 2025, 22:18 UTC

Discorsi di Mercato

RBA Set To Conclude Year With Hawkish Message -- Market Talk

6 dic 2025, 16:52 UTC

Acquisizioni, Fusioni, Takeovers

As Netflix Swoops In to Buy Warner Bros., We Revisit the Studio's Long, Twisted Journey -- Barrons.com

6 dic 2025, 10:30 UTC

Acquisizioni, Fusioni, Takeovers

Why Netflix Shareholders Aren't Thrilled to Acquire Warner Bros. -- Heard on the Street -- WSJ

6 dic 2025, 02:38 UTC

Acquisizioni, Fusioni, Takeovers

How a Netflix-Warner Deal Would Change Everything in Hollywood -- Again -- WSJ

5 dic 2025, 21:59 UTC

Acquisizioni, Fusioni, Takeovers

Netflix's Megadeal Will Need the Trump Administration's Blessing -- Update

5 dic 2025, 21:50 UTC

Discorsi di Mercato

Utili

Financial Services Roundup: Market Talk

5 dic 2025, 21:50 UTC

Acquisizioni, Fusioni, Takeovers

The Netflix and Warner Bros. Deal Is Far From a Sure Thing -- Barrons.com

5 dic 2025, 21:36 UTC

Discorsi di Mercato

Return of Shipping to Red Sea a Step Closer, Xeneta Says -- Market Talk

5 dic 2025, 21:35 UTC

Acquisizioni, Fusioni, Takeovers

The Netflix-Warner Bros. Deal Has a Wildcard. How Paramount Could Still Win. -- Barrons.com

5 dic 2025, 21:26 UTC

Acquisizioni, Fusioni, Takeovers

Warner Bros. Discovery and Netflix Enter Exclusive Deal Negotiations -- 7th Update

5 dic 2025, 21:12 UTC

Discorsi di Mercato

Natural Gas Surge 9% This Week on Strong Flow of Exports -- Market Talk

5 dic 2025, 21:03 UTC

Discorsi di Mercato

Utili

Bank of Montreal Logs Solid Quarter, Though Some Unease Remains -- Market Talk

5 dic 2025, 21:01 UTC

Discorsi di Mercato

Oil Caps Positive Week on Geopolitical Turmoil -- Market Talk

5 dic 2025, 20:43 UTC

Acquisizioni, Fusioni, Takeovers

Limitless CEO Siroker: Will No Longer Sell Pendant to New Customers

5 dic 2025, 20:43 UTC

Acquisizioni, Fusioni, Takeovers

Limitless CEO Siroker: Existing Pendant Customers to Be Supported for at Least Another Year

5 dic 2025, 20:42 UTC

Acquisizioni, Fusioni, Takeovers

Limitless CEO Dan Siroker: Limitless Has Been Acquired by Meta >META

5 dic 2025, 20:01 UTC

Acquisizioni, Fusioni, Takeovers

Netflix Landed a Big Deal. Now it Could Have a Big Fight. -- WSJ

5 dic 2025, 19:44 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

5 dic 2025, 19:44 UTC

Discorsi di Mercato

Canada Dollar Gains Nearly 1% on Jobs Data, Rate Outlook -- Market Talk

5 dic 2025, 19:39 UTC

Discorsi di Mercato

Silver Climbs to a New Record High -- Market Talk

5 dic 2025, 19:31 UTC

Acquisizioni, Fusioni, Takeovers

Netflix Stock Falls. Wall Street Is Worried About Warner Deal's High Price and Debt. -- Barrons.com

5 dic 2025, 18:30 UTC

Discorsi di Mercato

Canada Jobless Rate Can Fall More Before Labor Slack Disappears -- Market Talk

5 dic 2025, 18:28 UTC

Acquisizioni, Fusioni, Takeovers

Netflix Stock Falls. Wall Street Is Worried About Warner Deal's High Price and Debt. -- Barrons.com

5 dic 2025, 18:24 UTC

Acquisizioni, Fusioni, Takeovers

AMC and IMAX Stocks Drop. Roku Rises. How the Netflix-Warner Bros. Deal Could Shake Up Entertainment. -- Barrons.com

Confronto tra pari

Modifica del prezzo

Cassava Sciences Inc Previsione

Obiettivo di Prezzo

By TipRanks

150.78% in crescita

Previsioni per 12 mesi

Media 8 USD 150.78%

Alto 8 USD

Basso 8 USD

Basato su 1 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Cassava Sciences Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

1 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 1 che hanno fornito valutazioni azionarie a Cassava Sciences Inc - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

1.56 / 1.7Supporto e resistenza

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Sentiment

By Acuity

105 / 374 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Cassava Sciences Inc

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.